Career Invetor New Partner Merchandie Healthcare Profeional Connect with U earch

Your Health Our cience Our People Our Purpoe Our Product

NW / Pfizer Initiate Phae 1 tud of Novel Oral Antiviral Therapeutic Agent Againt AR-CoV-2

PFIZR INITIAT PHA 1 TUDY OF NOVL ORAL ANTIVIRAL

THRAPUTIC AGNT AGAINT AR-COV-2
Tueda, March 23, 2021 - 11:00am

In-vitro tudie conducted to date how that the clinical candidate PF-07321332 i a potent proteae inhiitor with potent anti-viral activit againt AR-CoV-2

Hide Thi i the firt orall adminitered coronaviru-pecific invetigational proteae inhiitor to e evaluated in clinical tudie, and follow Pfizer’ intravenoul adminitered
invetigational proteae inhiitor, which i currentl eing evaluated in a Phae 1 multi-doe tud in hopitalized clinical trial participant with COVID-19

NW YORK--(UIN WIR)-- Pfizer Inc. (NY: PF) announced toda that it i progreing to multiple acending doe after completing the doing of ingle acending doe
in a Phae 1 tud in health adult to evaluate the afet and tolerailit of an invetigational, novel oral antiviral therapeutic for AR-CoV-2, the viru that caue COVID-19.
Thi Phae 1 trial i eing conducted in the United tate. The oral antiviral clinical candidate PF-07321332, a AR-CoV2-3CL proteae inhiitor , ha demontrated potent in
vitro anti-viral activit againt AR-CoV-2, a well a activit againt other coronavirue, uggeting potential for ue in the treatment of COVID-19 a well a potential ue to
addre future coronaviru threat.

“Tackling the COVID-19 pandemic require oth prevention via vaccine and targeted treatment for thoe who contract the viru. Given the wa that AR-CoV-2 i mutating
and the continued gloal impact of COVID-19, it appear likel that it will e critical to have acce to therapeutic option oth now and eond the pandemic,” aid Mikael
Dolten, MD, PhD., Chief cientific Officer and Preident, Worldwide Reearch, Development and Medical of Pfizer. “We have deigned PF-07321332 a a potential oral
therap that could e precried at the firt ign of infection, without requiring that patient are hopitalized or in critical care. At the ame time, Pfizer’ intravenou antiviral
candidate i a potential novel treatment option for hopitalized patient. Together, the two have the potential to create an end to end treatment paradigm that complement
vaccination in cae where dieae till occur.”

Proteae inhiitor ind to a viral enzme (called a proteae), preventing the viru from replicating in the cell. Proteae inhiitor have een effective at treating other viral
pathogen uch a HIV and hepatiti C viru, oth alone and in comination with other antiviral. Currentl marketed therapeutic that target viral proteae are not generall
aociated with toxicit and a uch, thi cla of molecule ma potentiall provide well-tolerated treatment againt COVID-19.

The Phae 1 trial i a randomized, doule-lind, ponor-open, placeo-controlled, ingle- and multiple-doe ecalation tud in health adult evaluating the afet,
tolerailit and pharmacokinetic of PF-07321332.

Initiation of thi tud i upported  preclinical tudie that demontrated the antiviral activit of thi potential firt-in-cla AR-CoV-2 therapeutic deigned pecificall to
inhiit replication of the AR-CoV2 viru. The tructure of PF-07321332, together with the pre-clinical data, will e hared in a COVID-19 eion of the pring American
Chemical ociet meeting on April 6.

Pfizer i alo invetigating an intravenoul adminitered invetigational proteae inhiitor, PF-07304814, which i currentl in a Phae 1 multi-doe trial in hopitalized
clinical trial participant with COVID-19.

Aout Pfizer: reakthrough That Change Patient’ Live

At Pfizer, we appl cience and our gloal reource to ring therapie to people that extend and ignificantl improve their live. We trive to et the tandard for qualit,
afet and value in the dicover, development and manufacture of health care product, including innovative medicine and vaccine. ver da, Pfizer colleague work
acro developed and emerging market to advance wellne, prevention, treatment and cure that challenge the mot feared dieae of our time. Conitent with our
reponiilit a one of the world' premier innovative iopharmaceutical companie, we collaorate with health care provider, government and local communitie to
upport and expand acce to reliale, affordale health care around the world. For more than 170 ear, we have worked to make a difference for all who rel on u. We
routinel pot information that ma e important to invetor on our weite at www.Pfizer.com. In addition, to learn more, pleae viit u on www.Pfizer.com and follow u
on Twitter at @Pfizer and @Pfizer New , LinkedIn , YouTue and like u on Faceook at Faceook.com/Pfizer .

DICLOUR NOTIC: The information contained in thi releae i a of March 23, 2021. Pfizer aume no oligation to update forward-looking tatement contained in thi releae
a the reult of new information or future event or development.

Thi releae contain forward-looking information aout Pfizer’ effort to comat COVID-19, Pfizer’ oral antiviral clinical candidate PF-07321332, a AR-CoV2-3CL proteae
inhiitor, and Pfizer’ intravenoul adminitered invetigational proteae inhiitor, PF-07304814, involving utantial rik and uncertaintie that could caue actual reult to differ
materiall from thoe expreed or implied  uch tatement. Rik and uncertaintie include, among other thing, the uncertaintie inherent in reearch and development,
including the ailit to meet anticipated clinical endpoint, commencement and/or completion date for clinical trial, regulator umiion date, regulator approval date and/or
launch date, a well a rik aociated with preclinical and clinical data (including the in vitro data), including the poiilit of unfavorale new preclinical, clinical or afet data
and further anale of exiting preclinical, clinical or afet data; the ailit to produce comparale clinical or other reult; the rik that preclinical and clinical trial data are uject
to differing interpretation and aement, including during the peer review/pulication proce, in the cientific communit generall, and  regulator authoritie; whether
regulator authoritie will e atified with the deign of and reult from thee and an future preclinical and clinical tudie; whether and when an drug application for an
potential indication for PF-07321332 or PF-07304814 ma e filed in an juridiction; whether and when regulator authoritie in an juridiction ma approve an application
for PF-07321332 or PF-07304814, which will depend on mriad factor, including making a determination a to whether the product’ enefit outweigh it known rik and
determination of the product’ efficac and, if approved, whether it will e commerciall ucceful; deciion  regulator authoritie impacting laeling or marketing,
manufacturing procee, afet and/or other matter that could affect the availailit or commercial potential of PF-07321332 or PF-07304814, including development of product or
therapie  other companie; uncertaintie regarding the impact of COVID-19 on Pfizer’ uine, operation and financial reult; and competitive development.

A further decription of rik and uncertaintie can e found in Pfizer’ Annual Report on Form 10-K for the fical ear ended Decemer 31, 2020 and in it uequent report on
Form 10-Q, including in the ection thereof captioned “Rik Factor” and “Forward-Looking Information and Factor That Ma Affect Future Reult”, a well a in it uequent
report on Form 8-K, all of which are filed with the U.. ecuritie and xchange Commiion and availale at www.ec.gov and www.pfizer.com.

View ource verion on uinewire.com : http://www.uinewire.com/new/home/20210323005644/en/

Media Contact:
Pamela iele
+1 (347) 244-0271
Pamela.iele@Pfizer.com

Invetor Contact:
Chuck Triano
+1 (212) 733-3901
Charle..Triano@Pfizer.com

ource: Pfizer Inc.

YOUR HALTH OUR CINC OUR POPL OUR PURPO OUR PRODUCT CARR-KR
INVTOR
Health Living Therapeutic Area Meet the xpert Commitment To Gloal Health Product Liting
NW & MDIA
Dieae Condition Product Pipeline The Journe Poition on Health Policie How Drug are Made
PARTNR
Manage Your Health Clinical Trial Leaderhip Tranparenc Ditriutor
MRCHANDI
R&D Platform Divere Perpective Contriution & Partnerhip Gloal Product Information
HALTHCAR PROFIONAL
Contact
Collaoration UIN TO UIN
Merchandie
Reearch Ite CHANG RGION
ITMAP

CONTACT U
TRM OF U
PRIVACY POLICY

Copright © 2002-2021 Pfizer Inc. All right reerved. Thi information—including product information—i intended onl for reident of the United tate.
The product dicued herein ma have different laeling in different countrie.

Don’t Forget to Rate U

If ou enjo with our product, give u 5 tar. It help o much!
Rate U
Not Now